CPRX News and Press, Catalyst Pharmaceuticals Inc. From 07/26/21

CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare di...

The USPTO has issued a new patent for Catalyst Pharmaceuticals' (CPRX) Firdapse (amifampridine) Tablets 10mg, U.S. Patent No. 11,060,128, Methods of Administering 3,4-diaminopyridine. “This patent is directed to innovative methods of administering amifampridine to slow metabolizers of ...

New patent bolsters intellectual property protection for Firdapse® First in a family of four pending patents for Firdapse® to issue CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a...

CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...

Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $6.06. Approximately 301,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses...

Catalyst Pharmaceuticals (CPRX) announces the appointment of Molly Harper to the company’s board of directors.Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies.Since May 2020, she has served as Executiv...

CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...

Catalyst Pharmaceuticals (CPRX) comments on the recent decision by Health Canada to re-issue a Notice of Compliance ("NOC") for the company's rival drug Ruzurgi (amifampridine tablets), which is indicated to treat patients with Lambert-Eaton Myasthenic Syndrome ((LEMS)).The drug's o...

CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare ...

Shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at a new 52-week high today of $6.17. This new high was reached on below average trading volume as 301,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares. Catalyst Pharmaceuticals Inc. ...